Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Unknown 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 24Myelodysplastic Syndromes 5Leukemia, Biphenotypic, Acute 5Leukemia, Myelomonocytic, Chronic 3Neoplasm, Residual 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Carcinoma, Hepatocellular 2Blast Crisis 2Sarcoma, Myeloid 1Recurrence 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Down Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 8fludarabine phosphate 7fludarabine 5Busulfan 5Mycophenolic Acid 4Melphalan 4Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Filgrastim 3Azacitidine 3venetoclax 2thymoglobulin 2Tacrolimus 2Rituximab 2Injections 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Cytarabine 2Cyclosporins 2Clofarabine 2Bone Marrow Transplantation 2Antilymphocyte Serum 2sulforaphane 1ruxolitinib 1pegylated granulocyte colony-stimulating factor 1monalizumab 1ivosidenib 1enasidenib 1cedazuridine 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Anemia, Refractory, with Excess of Blasts × Idarubicin × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡